Micar21

Micar21 Micar Innovation is a drug discovery factory. The company has found a niche where it is able to crea Medicines are getting more expensive to develop.

These days, it takes about $1 billion and 10-12 years for a single new drug. Simulating millions of virtual medicines to find potential commercial candidates in weeks? That what we call truly transformative. Micar Innovation aims to change that by using all novel advanced approaches supported also by own drug discovery screen technology and GPU power to predict, in advance, which potential drug candidate molecule will work, and which won't. The same is valid for an innovative cosmetics active substance. Our technology can tell the difference between great drug candidates and toxic ones, and discover new uses for old medicines. The result is fewer test tubes, fewer experiments, fewer failed drugs. Just new and better medicines, faster. Micar Innovation can help discover and than predict the effectiveness of new potential drug molecules, reducing the need for costly and time-consuming physical synthesis and testing. With Micar Innovation rapid growth comes opportunities for organizations seeking new medicines or cosmetics active substances to work with the company. Micar Innovation is now inviting proposals for drug discovery collaborations from both private and public institutions. The company is also actively recruiting in the multidisciplinary areas of big data, bio informatics, computational biology, molecular dynamics, molecular modeling, medicinal chemistry, sctructural biology, precise free energy calculations, business development, sales and partnerships. Our own technology included multidisciplinary sciences and our we have many scientific publications. The same technology work not only for humans new drug, we use our technology for medicinal cosmetics and for animal drugs.

Our new manuscript about the binding of Omicron's RBD to ACE2 has been uploaded on BioRxiv in Wednesday
09/12/2021

Our new manuscript about the binding of Omicron's RBD to ACE2 has been uploaded on BioRxiv in Wednesday

The mutations in the spike protein of SARS-CoV-2 Omicron variant (B.1.1.529 lineage) gave rise to questions, but the data on the mechanism of action at the molecular level is limited. In this study, we present the Free energy of perturbation (FEP) data about the RBD-hACE2 binding of this new variant...

01/12/2021

The High Transmission of SARS-CoV-2 Omicron (B.1.1.529 lineage) Variant is Not Due Only to the ACE2 binding: A Free Energy of Perturbation Study

The mutations in the spike protein of SARS-CoV-2 Omicron variant (B.1.1.529 lineage) gave rise to questions, but the data on the mechanism of action at the molecular level is limited. In this study, we present the Free energy of perturbation (FEP) data about the RBD-hACE2 binding of this new variant.
We identified two groups of mutations located close to the most contributing substitutions Q498R and Q493R, which altered significantly the RBD-hACE2 interactions. The Q498R, Y505H, G496S mutations, in addition to N501Y, highly increased the binding to hACE2. They enhanced the binding by 98, 14 and 13 folds, respectively, which transforms the S1-RBD to a picomolar binder. However, in contrast to the case in mice the Q493R/K mutations, in a combination with K417N and T478K, dramatically reduced the S1 RBD binding by over 100 folds. Thus, the total effect of all these nine mutations located on the interaction surface of RBD-hACE2 turns out to be similar to that observed in the Alpha variant. It could be further specifically altered by the E484A mutation and even a similar to the wild type binding may also be detected. We provide a structural basis of the observed changes.
These data may explain only partially the observed in South Africa extremely high Omicron spread and is in support to the hypothesis for multiple mechanisms action involved in the transmission.

Our preliminary FEP data showed that the SARS-CoV-2 Omicron’s (B.1.1.529 lineage) G498R, Y505H and G496S mutations drast...
28/11/2021

Our preliminary FEP data showed that the SARS-CoV-2 Omicron’s (B.1.1.529 lineage) G498R, Y505H and G496S mutations drastically increase the binding to ACE2, which is an indication of its transmission. They enhanced the binding by 98, 14 and 13 times, respectively, which transforms the S1-RBD to a picomolar binder! Our estimations are based on the structures of both Alpha and Beta variants. The K417N and T478K had a relatively small negative effect to the binding: ddG=0.44 and +0.16 kacl/mol, respectively. Initially, we are calculating the contribution of the individual mutations to the RBD-ACE2 interactions and next we will do that for their total cumulative effect. Also, we expect an improvements of the results after the multi-site FEP calculations due to the cycle closure data. Currently, we observed a difference only for G496S which has a ddG= -0.82 and -0.23 kcal/mol in Alpha and Beta variants, most likely due to the not good convergence in Beta. We will improve that during the next hours and expect the data for Q493K. The latter and Glu484Ala and Lys417Asn can be described as an individual hot spot of mutations.

!!!!Мутациите на новия Ковид-19 вариант B.1.1.529 променят вируса до неузнаваемост!!!! Необходими са спешни мерки и затв...
26/11/2021

!!!!Мутациите на новия Ковид-19 вариант B.1.1.529 променят вируса до неузнаваемост!!!!

Необходими са спешни мерки и затваряне на границите ни с рисковите държави

Единадесетте мутации на B.1.1.529 (Ню) варианта на Ковид-19 в свързващия домейн на SARS-CoV-2 преобразят вируса до неузнаваемост. Повечето от тях са разположени на повърхността на свързване на вируса с човешките клетки през така наречения ACE2 рецептор. Това показват първоначалните анализи на наши експерти на последните налични структури на тази част на вируса, които са достъпни от преди едва двадесет дни. Те ще засегнат сериозно и повечето типове антитела.
Промяната на вируса е наистина много значима. Макар и някои от мутациите да са вече известни то за други няма никакви данни, а всичките те са разположени в региона който допринася за разпространението му. Казано на прост език в това важно отношение този вариант може да се сравни с преобразуването на тази част на вируса до нов вид коронавирус, коментира д-р Филип Фратев. Поради това нашите учени сформират международен екип, който да обедини усилия и ресурси и ще предоставят безвъзмездно данни само до няколко дни. Те ще спомогнат за решението на компетентни органи относно евентуалното затваряне на България за пътници от редица чужди страни. Подобен подход днес беше предложен и от ЕК.
През Декември 2020г. нашите учени бяха едни от първите, които дадоха сериозни данни за Английския и Южноафрикански варианти. Статията им, която първоначално беше публикувана като препринт, а после и в престижно научно списания, предизвика голям интерес в научната общност. Изследването беше отразено в повечето водещи световни медии. Според последните управляващия на пандемичната обстановка учен на Южноафриканската република е спрял играта си на крикет за да се запознае труда на българите. По-късно същия екип от наши учени предостави данни и за Мю варианта на вируса.

Очаквайте данните и подробности! Споделяте ако решите,че е важно за обществото!

A new study about the R346K Mutation in the Mu Covid-19 variant has been posted on October 13. Mean time our manuscript ...
11/11/2021

A new study about the R346K Mutation in the Mu Covid-19 variant has been posted on October 13. Mean time our manuscript about N501Y and K417N mutations received 47 citations, over 35 100 views on BiorXiv and was accepted for publication in JCIM (IF=5) today.

The Mu variant of SARS-CoV-2 has been recently classified as a variant of interest (VOI) by the world health organization (WHO) but limited data are available at the moment. In particular, a special attention was given to the R346K mutation located in the receptor binding domain (RBD). In the curren...

21/06/2021

We want to provide example of science validation of the capability and speed of Micar21 Drug Discovery Platform, which can be viewed and validated through science publications.

Early of December no one had accurate data on the effect of the new Covid19 - UK & South Africa mutations on the action of vaccines and on the binding of the virus to ACE2, so Micar21 decided to calculate pro-bono and support science worldwide.

On 16.12.2020 - Micar21 starts insilico calculations.
On 26.12.2020 - first version of our science publication - with calculation for English mutation COVID19.
On 31.12.2020 - second version of our science publication - with calculation for South African mutation COVID19 is included and we published our scientific publication:

https://www.biorxiv.org/content/10.1101/2020.12.23.424283v2.article-metrics

Dr. Filip Fratev (Micar21) is the sole author of the science publication. In less than 5 months there are already 22 citations (very good result).

Our competitors appeared with insilico data for Covid19 Mutations at the end of January 2021 (can be traced through science publications)

On 14.02.2021 (sent on 14.02.2021 - published on 23.02.2021) science publication by Oxford, validates Micar21 insilico results with experimental data:

https://www.cell.com/cell/pdf/S0092-8674(21)00226-9.pdf

Here, through the experimental data, our Micar21 insilico data calculated in December 2020 are proved.

Micar21 predicted in silico the stronger N501Y mutant binding to ACE2 (-1.42 kcal/mol) whereas months later experimental data shown a value of (-1.40 kcal/mol), thus, confirming that our in silico results was precise.

The aim of Micar21 study and new paper was to provide urgently high quality data about the effect of the UK and South African mutations. However, during the process of revision of the paper many experimental studies became available which was an excellent opportunity for a validation of the in silico approaches employed here and in particular protein-protein FEP. Also, we can compare our results to other data obtained by theoretical approaches which can be viewed and validated through other science publications and showed in our new science publication in Journal of Chemical Information and Modelling - under final review

http://micar21.com/Covid19_UK_SA_mutation.pdf

5100 виждания за няколко дена показва какво се прави в Micar21. ЧНГ на всички!
03/01/2021

5100 виждания за няколко дена показва какво се прави в Micar21. ЧНГ на всички!

The N501Y and K417N mutations in spike protein of SARS-CoV-2 and their combination arise questions but the data about their mechanism of action at molecular level is limited. Here, we present Free energy perturbation (FEP) calculations for the interactions of the spike S1 receptor binding domain (RB...

Анализирането на научни проблеми трябва да става възоснова на научни данни, а не на общи приказки!! В Микар21 твърдо вяр...
23/12/2020

Анализирането на научни проблеми трябва да става възоснова на научни данни, а не на общи приказки!! В Микар21 твърдо вярваме в това и се придържаме към този модел на работа!

Това са предварителни данни, а сред изследователите е член на фирма, чийто проект беше представен в началото на пандемията като възможно оръжие на науката ни срещу ...

Обидно е като си вложил много, държавата да не те е подкрепила и с една стотинка и после да говориш така. Ние можем да д...
26/04/2020

Обидно е като си вложил много, държавата да не те е подкрепила и с една стотинка и после да говориш така. Ние можем да докажем нещата с факти. Чакаме дата, на която и БАН ще подкрепят "разработката" си. Има огромна разлика между фирма, където трябва да се правят реални неща, и научна организация, която 30г само усвоява парите на българските граждани, има имаргенерни разработки, не е в полза на обществото и подава отчети...

Гледай ти

Химиците от фармацията са щели тепърва да намерят дигитално молекули, които да са тествани. Такива хора там, с нужните у...
12/04/2020

Химиците от фармацията са щели тепърва да намерят дигитално молекули, които да са тествани. Такива хора там, с нужните умения, Няма! Фейк новина в края на кризата. Ние сме намерили още преди месец, включително природни такива, но шефа на БАН не организира нужната колоборация. Правителството пасува. Няма да има българска разработка защото това, което ние направихме се иска сега дори и от Руската Федерация...Правителствата на ред други държави и много частни инвеститори.

Институтът

Address

38A Karamfil Street
Sofia
1616

Alerts

Be the first to know and let us send you an email when Micar21 posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Micar21:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Micar Innovation is a drug discovery factory

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through new blockbuster drug molecules for a large class of diseases. Micar Innovation focuses on non-clinical Proof-of-Concepts (POCs) in preclinical R&D and Hit-to-Lead (H2L) achievements in areas such as neuroscience, oncology, cardio-vascularity, dermatology, rare diseases. Micar21 is our drug discovery platform for small molecule drug candidates. The business model is based on licensing our intellectual property to commercial partners and on the creation new spin out companies.

Micar Innovation received the CIDIC award for its well-chosen positioning in a complex and long value chain, where it can create key-value contributions by delivering non-clinical POCs. The company can be qualified as a fountain of intellectual property and an IP broker for new pharma startups and big pharma industry.